

otherwise include all the limitations of an allowed generic claim as provided under 37 C.F.R. § 1.141.

REMARKS

Claims 35-51 were pending in the application, with Claim 35 being independent. Upon entry of these amendments, Claims 35-51 will be pending and under active consideration.

Claims 35-51 are readable upon the elected antibody species, OX-43.

AUTHORIZATION

Applicants believe there is no additional fee due in connection with this filing. However, to the extent required, the Commissioner is hereby authorized to charge any fees due in connection with this filing to Deposit Account 50-1710 or credit any overpayment to same.

Respectfully submitted,



Robert R. Seabold, Ph.D.
Registration No. 41,298
Gilberto M. Villacorta, Ph.D.
Registration No. 34,038

Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, Illinois 60661-3693
Facsimile: (312) 902-1061

Dated: December 12, 2002

EXHIBIT A

**CLAIMS WHICH WILL BE PENDING UPON ENTRY OF THE PRESENT
AMENDMENTS FILED DECEMBER 12, 2002
U.S. PATENT APPLICATION NO. 09/873,286**

35. A method of enriching for hepatic progenitors from liver comprising:
- (a) preparing a suspension of liver cells; and
 - (b) panning said suspension utilizing antibodies specific for hemopoietic cells, mesenchymal cells, mature liver cells, or combinations thereof, to remove said hemopoietic cells, mesenchymal cells, mature liver cells, or combinations thereof, from said suspension such that said suspension is enriched in hepatic progenitors.
36. The method of claim 35 wherein the mesenchymal cells comprise endothelial cells.
37. The method of claim 35 wherein the mature liver cells comprise at least one of hepatocytes and bile duct cells.
38. The method of claim 35 which further comprises performing multiparametric fluorescence activated cell sorting on said suspension utilizing at least one antibody to a hepatic cell marker, side scatter, forward scatter, autofluorescence, or combinations thereof.
39. The method of claim 35 wherein the antibody specific for hemopoietic cells is a monoclonal antibody.
40. The method of claim 35 wherein said single cell suspension comprises an agent capable of removing calcium from liver cell surface.

41. The method of claim 35 wherein said single cell suspension comprises EGTA.
42. The method of claim 35 wherein said single cell suspension comprises an enzyme capable of dissociating liver cells.
43. The method of claim 35 wherein said single cell suspension contains collagenase.
44. The method of claim 35 wherein said single cell suspension is chilled.
45. The method of claim 35 wherein said single cell suspension is at a temperature of between about 2 and 20 °C.
46. The method of claim 35 wherein the liver is neonatal liver.
47. method of claim 35 wherein the liver is embryonic liver.
48. The method of claim 35 wherein the liver is adult liver.
49. The method of claim 39 wherein said monoclonal antibody is at least one of OX-43 and OX-44.
50. The method of claim 35 wherein the antibody to a hepatic cell marker is monoclonal antibody 374.3
51. The method of claim 35 wherein said hepatic cell marker is OC.3.